A Study to Determine the Best Individualized Cancer Therapy Using Circulating Tumor DNA (ctDNA) in Patients with GI, CNS, and Thoracic Cancers.


About this study

This study proposes to develop and maintain a biorepository of blood samples collected from patients receiving definitive chemoradiotherapy for locally advanced rectal cancer, non-small cell lung cancer, or cervical cancer. The ultimate goal of this biorepository will be to provide the resource to initiate an exploration of ctDNA as a potential liquid biopsy for GI and Thoracic malignancy detection and surveillance.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  1. Adult patients (> 18 years of age) receiving definitive chemoradiotherapy at Mayo Clinic Florida
  2. Patients with tumors with a risk of local persistence of disease after therapy in the following areas:
    1. Locally advanced rectal cancer (T3-4NxM0; TxN+M0)
    2. Locally advanced non-small cell lung cancer
    3. High grade brain and spine tumors
    4. Locally advanced cervical cancer treated with primary radiotherapy

Exclusion Criteria: 

  1. Adult patients not willing/able to provide informed consent
  2. Patients <18 years of age
  3. Patients with HIV infection or Hepatitis infection

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Byron May, M.D.

Open for enrollment

Contact information:

Anna Harrell



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer